This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Amedisys (AMED) Q1 Earnings Beat, Operating Margin Falls
by Zacks Equity Research
Amedisys (AMED) notes that COVID-19 started impacting its volumes and costs beginning the second half of March.
Amedisys (AMED) Beats Q1 Earnings Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 8.25% and -4.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include: Vertex Pharmaceuticals, Alibaba, Amedisys and Fabrinet
by Zacks Equity Research
Zacks.com featured highlights include: Vertex Pharmaceuticals, Alibaba, Amedisys and Fabrinet
Scoop Up These 4 Stocks With Amazing Interest Coverage Ratio
by Sumit Singh
Interest Coverage Ratio suggests how many times the interest could be paid from earnings and gauges the margin of safety a firm has for paying interest.
Zacks.com featured highlights include: NEE, FNV, AMED, ATO and COST
by Zacks Equity Research
Zacks.com featured highlights include: NEE, FNV, AMED, ATO and COST
Bet on These 5 Low Leverage Stocks to Avoid Huge Losses
by Zacks Equity Research
With the earnings season in full swing, the real challenge for an investor is determining whether an organization's debt level is sustainable.
Earnings Preview: Amedisys (AMED) Q1 Earnings Expected to Decline
by Zacks Equity Research
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Reasons Why Growth Investors Shouldn't Overlook Amedisys (AMED)
by Zacks Equity Research
Amedisys (AMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Quest Diagnostics (DGX) in Focus: Stock Moves 5.4% Higher
by Zacks Equity Research
Quest Diagnostics (DGX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Add These 4 Stocks With Remarkable Interest Coverage Ratio
by Sumit Singh
Debt, which is crucial for most of the companies to finance operations, comes at a cost called interest. Interest expense has a direct bearing on the profits of a company.
Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AMED) Outperforming Other Medical Stocks This Year?
Bet on These 5 Low Leverage Stocks as Q1 Earnings Starts
by Zacks Equity Research
To safeguard one's portfolio from notable losses, the real challenge for an investor is determining whether the organization's debt level is sustainable. A debt-free corporation is hard to find.
Amedisys (AMED) Is Up 8.62% in One Week: What You Should Know
by Zacks Equity Research
Does Amedisys (AMED) have what it takes to be a top stock pick for momentum investors? Let's find out.
Amedisys (AMED) Upgraded to Buy: Here's Why
by Zacks Equity Research
Amedisys (AMED) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Amedisys (AMED) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Amedisys (AMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Amedisys Gains on Expanding Hospice Arm, Favorable Demography
by Zacks Equity Research
Amedisys' (AMED) recent acquisitions in the Hospice arm aid the company's growth.
Amedisys (AMED) Stock Moves -0.87%: What You Should Know
by Zacks Equity Research
In the latest trading session, Amedisys (AMED) closed at $168.20, marking a -0.87% move from the previous day.
Here's Why You Should Retain Amedisys (AMED) Stock for Now
by Zacks Equity Research
Investor confidence is high in Amedisys (AMED) stock, thanks to solid prospects.
Why Is Amedisys (AMED) Down 16.2% Since Last Earnings Report?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to benefit from broad array of services and inorganic expansion. However, intense competition remains a woe.
Scoop Up These 5 Promising Interest Coverage Ratio Stocks
by Sumit Singh
Interest expense has a direct bearing on the profits of a company and the company's creditworthiness depends on how effectively it meets its interest obligations.
Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AMED) Outperforming Other Medical Stocks This Year?
3 Reasons Growth Investors Will Love Amedisys (AMED)
by Zacks Equity Research
Amedisys (AMED) possesses solid growth attributes, which could help it handily outperform the market.
Amedisys (AMED) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Amedisys (AMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).